- Home
- ATXS vs STK Comparison
ATXS vs STK Comparison
Compare ATXS & STK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATXS
- STK
- Stock Information
- Founded
- ATXS 2008
- STK 2009
- Country
- ATXS United States
- STK United States
- Employees
- ATXS N/A
- STK N/A
- Industry
- ATXS Biotechnology: Pharmaceutical Preparations
- STK Investment Managers
- Sector
- ATXS Health Care
- STK Finance
- Exchange
- ATXS Nasdaq
- STK Nasdaq
- Market Cap
- ATXS 584.1M
- STK 567.0M
- IPO Year
- ATXS 2015
- STK N/A
- Fundamental
- Price
- ATXS $9.55
- STK $32.56
- Analyst Decision
- ATXS Strong Buy
- STK
- Analyst Count
- ATXS 5
- STK 0
- Target Price
- ATXS $28.00
- STK N/A
- AVG Volume (30 Days)
- ATXS 340.4K
- STK 38.2K
- Earning Date
- ATXS 11-13-2024
- STK 01-01-0001
- Dividend Yield
- ATXS N/A
- STK 6.60%
- EPS Growth
- ATXS N/A
- STK N/A
- EPS
- ATXS N/A
- STK N/A
- Revenue
- ATXS N/A
- STK N/A
- Revenue This Year
- ATXS N/A
- STK N/A
- Revenue Next Year
- ATXS N/A
- STK N/A
- P/E Ratio
- ATXS N/A
- STK N/A
- Revenue Growth
- ATXS N/A
- STK N/A
- 52 Week Low
- ATXS $5.88
- STK $24.95
- 52 Week High
- ATXS $16.90
- STK $34.31
- Technical
- Relative Strength Index (RSI)
- ATXS 41.21
- STK 35.89
- Support Level
- ATXS $9.40
- STK $35.35
- Resistance Level
- ATXS $9.99
- STK $36.30
- Average True Range (ATR)
- ATXS 0.58
- STK 0.49
- MACD
- ATXS -0.01
- STK -0.21
- Stochastic Oscillator
- ATXS 9.32
- STK 1.32
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
About STK Columbia Seligman Premium Technology Growth Fund Inc
Columbia Seligman Premium Technology Growth Fund Inc is a closed-end management investment company. Its investment objective is to seek growth of capital and current income. The fund invests in various sectors such as consumer discretionary, industrials, information technology and telecommunication services. Columbia Management Investment Advisers, LLC serves as the investment manager to the fund.